JP2020513414A5 - - Google Patents

Download PDF

Info

Publication number
JP2020513414A5
JP2020513414A5 JP2019531825A JP2019531825A JP2020513414A5 JP 2020513414 A5 JP2020513414 A5 JP 2020513414A5 JP 2019531825 A JP2019531825 A JP 2019531825A JP 2019531825 A JP2019531825 A JP 2019531825A JP 2020513414 A5 JP2020513414 A5 JP 2020513414A5
Authority
JP
Japan
Prior art keywords
ingestible device
cecum
ingestible
tnf antibody
reservoir
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019531825A
Other languages
English (en)
Japanese (ja)
Other versions
JP7150724B2 (ja
JP2020513414A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/066485 external-priority patent/WO2018112240A1/en
Publication of JP2020513414A publication Critical patent/JP2020513414A/ja
Publication of JP2020513414A5 publication Critical patent/JP2020513414A5/ja
Priority to JP2022155282A priority Critical patent/JP2022177262A/ja
Application granted granted Critical
Publication of JP7150724B2 publication Critical patent/JP7150724B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019531825A 2016-12-14 2017-12-14 消化管疾病のtnf阻害薬による治療 Active JP7150724B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022155282A JP2022177262A (ja) 2016-12-14 2022-09-28 消化管疾病のtnf阻害薬による治療

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662434363P 2016-12-14 2016-12-14
US62/434,363 2016-12-14
US201762479118P 2017-03-30 2017-03-30
US62/479,118 2017-03-30
US201762545240P 2017-08-14 2017-08-14
US62/545,240 2017-08-14
US201762583768P 2017-11-09 2017-11-09
US62/583,768 2017-11-09
PCT/US2017/066485 WO2018112240A1 (en) 2016-12-14 2017-12-14 Treatment of a disease of the gastrointestinal tract with a tnf inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022155282A Division JP2022177262A (ja) 2016-12-14 2022-09-28 消化管疾病のtnf阻害薬による治療

Publications (3)

Publication Number Publication Date
JP2020513414A JP2020513414A (ja) 2020-05-14
JP2020513414A5 true JP2020513414A5 (enExample) 2021-01-28
JP7150724B2 JP7150724B2 (ja) 2022-10-11

Family

ID=60953957

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019531825A Active JP7150724B2 (ja) 2016-12-14 2017-12-14 消化管疾病のtnf阻害薬による治療
JP2022155282A Pending JP2022177262A (ja) 2016-12-14 2022-09-28 消化管疾病のtnf阻害薬による治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022155282A Pending JP2022177262A (ja) 2016-12-14 2022-09-28 消化管疾病のtnf阻害薬による治療

Country Status (11)

Country Link
US (1) US20190343425A1 (enExample)
EP (2) EP4410832A3 (enExample)
JP (2) JP7150724B2 (enExample)
KR (1) KR102616436B1 (enExample)
CN (2) CN118873822A (enExample)
AU (2) AU2017378393B2 (enExample)
BR (1) BR112019011689A2 (enExample)
CA (1) CA3045307A1 (enExample)
MX (1) MX2019006864A (enExample)
TW (1) TW201834711A (enExample)
WO (1) WO2018112240A1 (enExample)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2013158256A (ru) 2011-07-06 2015-07-10 Нестек С.А. АНАЛИЗЫ ДЛЯ ОБНАРУЖЕНИЯ НЕЙТРАЛИЗУЮЩИХ АУТОАНТИТЕЛ ДЛЯ БИОЛОГИЧЕСКОЙ ТЕРАПИИ TNFα
ES2735085T3 (es) 2014-12-05 2019-12-16 Nestle Sa Ensayos de cambio de movilidad homogéneos indirectos para la detección de agentes biológicos en muestras de pacientes
US20210138213A1 (en) * 2017-03-30 2021-05-13 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
US10980482B2 (en) 2017-12-06 2021-04-20 James Phillip Jones Sampling capsule system and methods
MA52366A (fr) 2018-04-25 2021-03-03 Prometheus Biosciences Inc Anticorps anti-tl1a optimisés
USD891632S1 (en) * 2018-10-08 2020-07-28 Tidhar Dari Shalon Gastrointestinal sampling device
JP2022554076A (ja) * 2019-10-08 2022-12-28 11 ヘルス アンド テクノロジーズ リミテッド 尿及び糞便を分析するためのシステム及び方法
JP7504992B2 (ja) 2019-10-24 2024-06-24 プロメテウス バイオサイエンシーズ,インク. Tnf様リガンド1a(tl1a)に対するヒト化抗体およびその使用
US20220313200A1 (en) * 2019-11-25 2022-10-06 Check-Cap Ltd. Sensor-less dc motor closed loop controller for imaging capsule
JP7444991B2 (ja) * 2019-12-16 2024-03-06 イーライ リリー アンド カンパニー 消化器サンプリングのためのカプセル
WO2021154815A1 (en) * 2020-01-27 2021-08-05 Celero Systems, Inc. Ingestible medical device
CA3166610A1 (en) 2020-01-31 2021-08-05 Masoud TAHGHIGHI JAFARZADEH An ingestible therapeutic device for the treatment of gastritis
WO2023205701A1 (en) 2022-04-20 2023-10-26 Kumquat Biosciences Inc. Macrocyclic heterocycles and uses thereof
KR102247483B1 (ko) * 2020-02-27 2021-05-04 주식회사 레인보우솔루션 경구형 물질 전달 장치
CN111714781B (zh) * 2020-06-24 2022-08-05 北京夏禾科技有限公司 一种牙齿美白组合及其使用方法
TWI768541B (zh) * 2020-11-12 2022-06-21 鄭靖蓉 引流淋巴液至靜脈之設備
WO2022109089A1 (en) * 2020-11-18 2022-05-27 Trustees Of Tufts College Spatially-selective sampling of gut microbiome
CN113040070A (zh) * 2020-12-15 2021-06-29 苏州大学 一种草鱼肠道菌群失调模型的建立方法
EP4389751A1 (en) 2021-09-03 2024-06-26 Kumquat Biosciences Inc. Heterocyclic compounds and uses thereof
CN115251807B (zh) * 2022-09-26 2022-12-06 徐州医科大学 胶囊内窥镜系统
WO2025007000A1 (en) 2023-06-30 2025-01-02 Kumquat Biosciences Inc. Substituted condensed tricyclic amine compounds and uses thereof as ras inhibitors
WO2025171055A1 (en) 2024-02-06 2025-08-14 Kumquat Biosciences Inc. Heterocyclic conjugates and uses thereof
DK182197B1 (en) * 2024-04-29 2025-11-14 Biograil ApS Oral drug delivery device with cover release
WO2025230971A1 (en) 2024-04-30 2025-11-06 Kumquat Biosciences Inc. Macrocyclic heterocycles as anticancer agents

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
IL47062A (en) 1975-04-10 1979-07-25 Yeda Res & Dev Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde
US4190328A (en) 1978-12-01 1980-02-26 Levine Robert A Process for detection of blood-borne parasites
US4665077A (en) 1979-03-19 1987-05-12 The Upjohn Company Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5116742A (en) 1986-12-03 1992-05-26 University Patents, Inc. RNA ribozyme restriction endoribonucleases and methods
US4987071A (en) 1986-12-03 1991-01-22 University Patents, Inc. RNA ribozyme polymerases, dephosphorylases, restriction endoribonucleases and methods
US4904582A (en) 1987-06-11 1990-02-27 Synthetic Genetics Novel amphiphilic nucleic acid conjugates
IL85746A (en) 1988-03-15 1994-05-30 Yeda Res & Dev Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases
FI891226A7 (fi) 1988-04-28 1989-10-29 The Board Of Trustees Of The Leland Anti-T-solun reseptorideterminantit autoimmuunisairauden hoitoon
JP2681061B2 (ja) 1988-06-08 1997-11-19 ロンドン・ダイアグノスティック・インコーポレーテッド 検出可能なシグナルのセンシタイザー誘導発生を利用したアッセイ
WO1990008187A1 (en) 1989-01-19 1990-07-26 Dana Farber Cancer Institute Soluble two domain cd2 protein
CA2046909A1 (en) 1989-03-21 1990-09-22 Mark D. Howell Vaccination and methods against diseases resulting from pathogenic responses by specific t cell populations
AU652540B2 (en) 1989-07-19 1994-09-01 Xoma Corporation T cell receptor peptides as therapeutics for autoimmune and malignant disease
AU630497B2 (en) 1989-09-05 1992-10-29 Immunex Corporation Tumor necrosis factor-alpha and -beta receptors
US5170801A (en) * 1990-10-02 1992-12-15 Glaxo Inc. Medical capsule device actuated by radio-frequency (rf) signal
US6251581B1 (en) 1991-05-22 2001-06-26 Dade Behring Marburg Gmbh Assay method utilizing induced luminescence
US5314805A (en) 1991-10-28 1994-05-24 Molecular Probes, Inc. Dual-fluorescence cell viability assay using ethidium homodimer and calcein AM
EP0656946B2 (en) 1992-08-21 2010-03-31 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
JPH07504203A (ja) 1992-09-15 1995-05-11 イミュネックス・コーポレーション 腫瘍壊死因子アンタゴニストを用いるtnf−依存性炎症の治療方法
US6180403B1 (en) 1999-10-28 2001-01-30 Isis Pharmaceuticals Inc. Antisense inhibition of tumor necrosis factor alpha converting enzyme (TACE) expression
US5705398A (en) 1994-03-02 1998-01-06 The Scripps Research Institute Methods for identifying inhibitors of LPS-mediated LBP binding
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DE69721548T2 (de) 1996-02-09 2004-04-01 Abbott Laboratories(Bermuda)Ltd. HUMANE ANTIKÖRPER WELCHE AN HUMANEN TNFalpha BINDEN
US5763602A (en) 1996-10-01 1998-06-09 Li; Ying-Syi Methods of syntheses of phthalocyanine compounds
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6046319A (en) 1997-10-22 2000-04-04 University Technologies International, Inc. Antisense oligodeoxynucleotides regulating expression of TNF-α
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AU2679899A (en) 1998-02-18 1999-09-06 Dade Behring Inc. Chemiluminescent compositions for use in detection of multiple analytes
US6228642B1 (en) 1998-10-05 2001-05-08 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of tumor necrosis factor-(α) (TNF-α) expression
US6080580A (en) 1998-10-05 2000-06-27 Isis Pharmaceuticals Inc. Antisense oligonucleotide modulation of tumor necrosis factor-α (TNF-α) expression
US8636648B2 (en) * 1999-03-01 2014-01-28 West View Research, Llc Endoscopic smart probe
US6331530B1 (en) 1999-07-13 2001-12-18 The Trustees Of Columbia University In The City Of New York Hydrophilic carrier for photosensitizers that cleaves when they catalyze the formation of singlet oxygen
US6703248B1 (en) 1999-12-15 2004-03-09 Dade Behring Marburg Gmbh Particles for diagnostic and therapeutic use
CA2435205A1 (en) * 2001-01-22 2002-08-01 V-Target Technologies Ltd. Ingestible device
US20050227935A1 (en) 2001-05-18 2005-10-13 Sirna Therapeutics, Inc. RNA interference mediated inhibition of TNF and TNF receptor gene expression using short interfering nucleic acid (siNA)
US7160258B2 (en) * 2001-06-26 2007-01-09 Entrack, Inc. Capsule and method for treating or diagnosing the intestinal tract
KR20040108655A (ko) 2002-03-05 2004-12-24 아클라라 바이오사이언시스 인코퍼레이티드 막-결합된 민감제를 사용하는 복합 분석법
CA2491355A1 (en) * 2002-07-05 2004-01-15 Temrel Limited Controlled release compositions comprising coated pellets having non-uniform coating thicknesses
CN101745112A (zh) * 2002-07-19 2010-06-23 艾博特生物技术有限公司 TNFα相关疾病的治疗
TWI250312B (en) 2002-10-11 2006-03-01 Delta Electronics Inc Illumination system with multiple lamps
US9211259B2 (en) 2002-11-29 2015-12-15 Foamix Pharmaceuticals Ltd. Antibiotic kit and composition and uses thereof
US7977471B2 (en) 2002-11-14 2011-07-12 Dharmacon, Inc. siRNA targeting TNFα
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
US7402398B2 (en) 2003-07-17 2008-07-22 Monogram Biosciences, Inc. Measuring receptor homodimerization
CN1874789A (zh) 2003-09-23 2006-12-06 光科学公司 用于光动力疗法的缀合物
BRPI0509271A (pt) * 2004-03-26 2007-09-04 Lek Pharmaceuticals formas de dosagens farmacêuticas gastrorresistentes compreendendo ácido n-(2-(2-ftalimidaetóxi)-acetil-l-alanil-d-glutámico(lk-4 23)
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
DE102004059613A1 (de) * 2004-12-10 2006-06-14 Liedtke, Rainer K., Dr. Zusammensetzung und Methode einer topischen Therapie von Neurodermitis
EP1841490A2 (en) * 2005-01-18 2007-10-10 Koninklijke Philips Electronics N.V. Electronically controlled capsule
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
TWI323734B (en) 2005-08-19 2010-04-21 Abbott Lab Dual variable domain immunoglobulin and uses thereof
CN101472639A (zh) * 2006-06-20 2009-07-01 皇家飞利浦电子股份有限公司 用于治疗胃肠疾病的电子胶囊
JP2009541018A (ja) * 2006-06-23 2009-11-26 コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ 薬剤投与システム
EP2484696B1 (en) 2006-08-28 2017-08-16 Kyowa Hakko Kirin Co., Ltd. Antagonistic hLIGHT-specific human monoclonal antibodies
WO2011004395A1 (en) 2009-07-06 2011-01-13 Intas Biopharmaceuticals Limited Microemulsion formulation for biologicals
JP6030956B2 (ja) * 2009-08-05 2016-11-24 テル ハショマー メディカル リサーチ インフラストラクチャー アンド サーヴィシーズ リミテッド 胃腸管の異常の診断に使える情報を提供する方法と機器
US9415004B2 (en) * 2010-12-23 2016-08-16 Rani Therapeutics, Llc Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device
US8907081B2 (en) 2011-05-27 2014-12-09 Sharp Laboratories Of America, Inc. Long wavelength absorbing porphyrin photosensitizers for dye-sensitized solar cells
US8884006B2 (en) 2011-09-19 2014-11-11 University Of Puerto Rico Small-molecule inhibitors of Rac1 in metastatic breast cancer
WO2013113326A1 (en) 2012-01-31 2013-08-08 Curevac Gmbh Pharmaceutical composition comprising a polymeric carrier cargo complex and at least one protein or peptide antigen
FR2986432B1 (fr) 2012-02-06 2014-03-14 Univ Lille Ii Droit & Sante Proteines 28kda gst provenant de schistosomes pour leur utilisation dans le traitement des maladies inflammatoires auto-immunes engendrant une reponse de type th1 et/ou th17
WO2013148350A2 (en) 2012-03-26 2013-10-03 Sanofi Anti-light antibody therapy for inflammatory bowel disease
US9962423B2 (en) * 2013-03-13 2018-05-08 Emory University Protein particles comprising disulfide crosslinkers and uses
JP6461787B2 (ja) 2013-04-12 2019-01-30 国立大学法人京都大学 肺胞上皮前駆細胞の誘導方法
RU2015155552A (ru) 2013-05-24 2017-06-27 Нестек С.А. Путеспецифические способы прогнозирования диагноза синдрома раздраженного кишечника
PL226431B1 (pl) 2013-08-23 2017-07-31 Inst Biochemii I Biofizyki Polskiej Akademii Nauk Cząsteczka miRNA do zastosowania do wytwarzania leku do zmniejszania reakcji zapalnej lub zapobiegania zwiększaniu się reakcji zapalnej organizmu
WO2015059569A1 (en) * 2013-09-26 2015-04-30 Medimetrics Personalized Drug Delivery, B.V. Delivery capsule with threshold release
GB201319792D0 (en) * 2013-11-08 2013-12-25 Sigmoid Pharma Ltd Formulations
CA2929784C (en) 2013-11-13 2019-11-26 Pfizer Inc. Tumor necrosis factor-like ligand 1a specific antibodies and compositions and uses thereof
US20160249793A1 (en) * 2013-12-27 2016-09-01 Kang-Huai Wang Capsule Camera Device with Multi-Spectral Light Sources
ES2923641T3 (es) 2013-12-30 2022-09-29 Epimab Biotherapeutics Inc Inmunoglobulina con Fabs en tándem y usos de la misma
US10219748B2 (en) 2014-01-22 2019-03-05 Nutech Ventures Gastrointestinal sensor implantation system
WO2015131078A1 (en) * 2014-02-27 2015-09-03 Biogen Ma Inc. Method of assessing risk of pml
CA2955666A1 (en) * 2014-08-13 2016-02-18 Cedars-Sinai Medical Center Anti-methanogenic compositions and uses thereof
AU2015319850B2 (en) * 2014-09-25 2019-09-26 Bt Bidco, Inc. Electromechanical pill device with localization capabilities
US9714288B2 (en) 2014-09-30 2017-07-25 The Regents Of The University Of California Antisense compounds and uses thereof
WO2016099792A1 (en) * 2014-11-19 2016-06-23 Nano Pharmaceutical Laboratories Llc Wireless communications system integrating electronics into orally ingestible products for controlled release of active ingredients
CN104473611B (zh) 2015-01-19 2018-01-30 吉林大学 具有超声波定位功能的胶囊内窥镜系统
KR20170122776A (ko) * 2015-03-06 2017-11-06 신세틱 바이오로직스, 인코퍼레이티드 마이크로바이옴 보호를 위한 안전하고 유효한 베타-락타마제 투약
JP6895421B2 (ja) 2015-03-31 2021-06-30 ブイエイチスクエアード リミテッド ポリペプチド
ES2716900T3 (es) * 2015-11-06 2019-06-17 Promise Advanced Proteomics Un método para cuantificar anticuerpos anti-TNF
HUE052869T2 (hu) 2016-03-17 2021-05-28 Tillotts Pharma Ag TNF-ellenes alfa-antitestek és ezek funkcionális fragmentjei
EP3435982A1 (en) 2016-03-31 2019-02-06 VHsquared Limited Compositions

Similar Documents

Publication Publication Date Title
JP2020513414A5 (enExample)
JP2020501699A5 (enExample)
JP2020502125A5 (enExample)
JP2020502126A5 (enExample)
JP2020515579A5 (enExample)
JP7150724B2 (ja) 消化管疾病のtnf阻害薬による治療
JP2022177262A5 (enExample)
Housseau et al. Enterotoxigenic Bacteroides fragilis (ETBF)-mediated colitis in Min (Apc+/-) mice: a human commensal-based murine model of colon carcinogenesis
JP2017532125A5 (enExample)
JP2017504590A5 (enExample)
ITBO930099A1 (it) Uso di rifaximin e di formulazioni che la contengono nel trattamento delle dispepsie gastriche originate da helicobacter pylori
CA3046019A1 (en) Treatment of a disease of the gastrointestinal tract with a tlr modulator
AR084610A1 (es) Comprimido de desintegracion oral de lansoprazol
CA3006380A1 (en) Methods of treating colitis
WO2004064717A3 (en) Cop 1 for treatment of inflammatory bowel diseases
MX2012014096A (es) Métodos para mejorar el diagnóstico de enfermedad intestinal inflamatoria.
JP2016502091A5 (enExample)
CA3045472A1 (en) Treatment of a disease of the gastrointestinal tract with a smad7 inhibitor
Marandi et al. Immunization against Vibrio cholerae, ETEC, and EHEC with chitosan nanoparticle containing LSC chimeric protein
US9534977B2 (en) Intraluminal pressure detection for diverticular disease
JP2009503045A5 (enExample)
Panarelli Other forms of esophagitis: it is not gastroesophageal reflux disease, so now what do I do?
EP2594277A4 (en) TABLET WITH IRON CITRATE
JP2017506265A5 (enExample)
Tapsall The biology of Neisseria gonorrhoeae: a model of adaptation and survival